{"entity":{"id":"nct04094610","kind":"trial","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","aka":[],"tldr":"A phase 1/2 trial of Repotrectinib in non-Hodgkin lymphoma and brain and spinal cord tumours, run by Turning Point Therapeutics, Inc., now recruiting.","summary":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations is a phase 1/2 interventional study registered as NCT04094610 by Turning Point Therapeutics, Inc., with 75 participants planned, started 2020-03-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Oral repotrectinib (TPX-0005).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04094610","url":"https://clinicaltrials.gov/study/NCT04094610"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["repotrectinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04094610","phase":"1/2","setting":"A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations","sponsor":"Turning Point Therapeutics, Inc.","enrolled":75,"outcomes":[]},"route":"/trials/nct04094610/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/"}]}}